WALTHAM, Mass.--(BUSINESS WIRE)--Adnexus Therapeutics, Inc. today announced that the company presented additional Phase I and preclinical data on Angiocept (CT-322), the company’s novel anti-angiogenesis agent, at The 6th International Congress on Targeted Therapies in Cancer that was held in Washington, DC at the Renaissance Mayflower Hotel August 24-26, 2007. The presentation titles and the associated speakers were as follows:
